AJ GROUP(SH:600643) Zheng Quan Ri Bao·2025-09-16 05:07Group 1 - The AiTech Forum focused on providing a clear pathway for Chinese pharmaceutical companies to expand internationally, with insights from global institutions and industry representatives [1][2] - Ireland is positioned as a regulatory hub for the EU, offering compliance guidance and local infrastructure support to assist Chinese pharmaceutical companies in entering the European market [1] - The International Drug Information Association (DIA) aims to facilitate deep cooperation among global regulatory bodies and support Chinese innovative drug companies in establishing a "dual circulation" model for international market access [1][2] Group 2 - The "three-tier service system" for technology transfer includes demand-side connections with hospitals and large enterprises, supply-side integration of university innovations, and service-side support for IP rights and global resource networks [2] - Local innovative pharmaceutical companies shared their strategies for international expansion, emphasizing the importance of product strength and market timing [2] - Companies are prioritizing emerging markets for vaccine registration and sales, while also developing new vaccine technologies [2] Group 3 - China is becoming a significant source of innovative drugs for multinational pharmaceutical companies, with advantages in regulatory alignment, cost efficiency, and innovation capabilities [3] - A strategic cooperation signing ceremony was held to create a platform for ongoing collaboration among government, enterprises, international institutions, and financial capital [3] - The goal is to accelerate the globalization of China's innovative drug industry and inject new momentum into the high-quality development of the biopharmaceutical sector [3]